1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

Executive Summary

Need for Effective Working Capital Management
•Decreasing profitability
•Fizzling innovation model
•Access to new markets
•Price premium pressure

Key Trends

•The analysis of Year-on-year (YOY) revenue growth shows that the growth in both North American and European industries declined between 2009 and 2013.
•In big pharma, US companies successfully reduced the days inventory outstanding by x % between 2009 and 2013, while European companies were able to reduce it by only x % in the same period.
•In 2013, mid-size companies were not able to reduce their days sales outstanding compared to previous years. Days sales outstanding for US companies increased by x % between 2009 and 2013.
•In smaller companies, the analysis of days sales outstanding reveals that US companies have a better receivable performance compared to European companies.

Key Terms Used in the Study

M&A: Mergers and acquisitions is an aspect of corporate strategy, corporate finance, and management by which corporations legally unify ownership of assets formerly subject to separate controls. The term “deal” in the study refers to M&A transactions.
Pharmaceutical Industry: Companies engaged in the research, development, or production of pharmaceuticals.
Days Inventory Outstanding: A financial measure of a company's performance that gives investors an idea of how long it takes a company to turn its inventory (including goods that are work in progress, if applicable) into sales.
Days Payable Outstanding: Days payable outstanding tells how long it takes a company to pay its invoices from trade creditors, such as suppliers.
Days Sales Outstanding: A measure of the average number of days that a company takes to collect revenue after a sale has been made.
Cash Conversion Cycle: A metric that expresses the length of time, in days, that it takes for a company to convert resource inputs into cash flows.

Objectives of the Study

Analyzing the working capital management trends in the North American and European pharma industry
Identifying the key trends in the industry based on geographies, across revenue segments
Conducting an analysis of various components of working capital management
To arrive at strategic conclusions based on the key trends observed

Table Of Contents

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency
Executive Summary 3
Introduction 6
The Key Rationale for effective Working Capital Management 11
Revenue Range Classification: Revenue Greater Than $10.00 Billion 16
Revenue Range Classification: Revenue Between $1.00 Billion and $10.00 Billion 22
Revenue Range Classification: Revenue Between $50.0 Million and $1.00 Billion 28
Conclusion 34
Appendix 36
The Frost and Sullivan Story 45

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.